๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hohhot
Clinical trial register · China

Clinical Trials in Hohhot, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5 Chengdu 5 Hohhot 5 Changchun 3 Changsha 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5 Chengdu5 Hohhot5 Changchun3 Changsha3
All 25 locations
Target enrolment
to

Trials with a site in Hohhot

5 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Active, closed
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
NCT06605885Asthma
AstraZeneca
Observational
202
Hohhot, Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou
2024-11-14
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Recruiting
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
NCT06419413Asthma
AstraZeneca
Observational
355
Chengdu, Beijing, Changsha, Dongguan, Foshan, Guangzhou, Hainan, Hohhot
2024-01-08
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/hohhot

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5 of those studies with a site in Hohhot that also match the filters currently applied.

How many clinical trials are recruiting in Hohhot?

4 of the 5 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hohhot), 5 studies
PhaseStudiesRecruitingShare
Observational2140%
Phase 32240%
Phase 21120%

Most active sponsors

Lead sponsors with the most studies (Hohhot)
Lead sponsorStudiesRecruiting
AstraZeneca54
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.